ArticleBiological psychiatry global open science2025
Antidepressant Switching as a Proxy Phenotype for Drug Nonresponse: Investigating Clinical, Demographic, and Genetic Characteristics.
Article in Biological psychiatry global open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genome-wide meta-analyses of non-response to antidepressants provide insights into underlying molecular genetics and suggest potential pharmacotherapies.Molecular psychiatry · 2026Pooled it
- Understanding antidepressant change patterns in the UK Biobank.The British journal of psychiatry : the journal of mental science · 2026Article
- Antidepressant use at the threshold: people prescribed antidepressants around the time of a dementia diagnosis.Age and ageing · 2026Article
- Primary adherence to medications for the treatment of major depressive disorder: A descriptive study using real-world data.Journal of managed care & specialty pharmacy · 2026Article
- Prescribed hormonal contraceptive use trends in the Estonian Biobank: A longitudinal observational study.PLoS medicine · 2026Observational
- Treatment resistant depression in electronic health records: definitions matter.BMC psychiatry · 2026Article
- Variant in a Taste Receptor Locus Tied to Changes in the Use of Insomnia Medication.Biological psychiatry global open science · 2026Article
- A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response Outcomes.Clinical and translational science · 2026Article
- Rethinking the Treatment-Resistant Depression.Advances in experimental medicine and biology · 2026Review
- Supporting complex mental health care and services research today and beyond: a mini-review of real-world evidence strategies and informed approaches.Frontiers in health services · 2026Review
- A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response Outcomes.medRxiv : the preprint server for health sciences · 2025Article
- Exploring depression treatment response by using polygenic risk scoring across diverse populations.American journal of human genetics · 2025Article
- Sociodemographic, clinical, and genetic factors associated with self-reported antidepressant response outcomes in the UK Biobank.Psychological medicine · 2025Article
- Polygenic scores and antidepressant treatment outcomes in major depression: a critical integrative review.Neuroscience applied · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Selective serotonin reuptake inhibitors (SSRIs) are a first-line pharmacological therapy in major depressive disorder (MDD), but treatment response rates are low. Clinical trials lack the power to study the genetic contribution to SSRI response. Real-world evidence from electronic health records provides larger sample sizes, but novel response definitions are needed to accurately define SSRI nonresponders. Methods: In the UK Biobank (UKB) ( Results: In the UKB, 5133 (13.2%) SSRI switchers and 33,680 nonswitchers were defined. The mean time to switch was 28 days (interquartile range, 17-49). Switching patterns were consistent across the UKB and Generation Scotland ( Conclusions: This study identified SSRI switching as a proxy for nonresponse, scalable across biobanks with electronic health records, capturing demographics and genetics of treatment nonresponse, and independent of MDD genetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.